Bioactive Compounds Against SARS CoV2 1st Edition by Jen Tsung Chen ISBN 9781000909098 1000909093

Chapter 1 Omics-Guided Intervention Strategies in Combatting SARS-CoV-2: Recent Advancements and Challenges

1.1 Introduction

1.2 Origin of SARS-CoV-2

1.3 Pathophysiology of COVID-19

1.4 Omics-Guided Therapeutic Strategies

1.5 Conclusions and Future Directives

Acknowledgments

References

Chapter 2 The Application of Computer-Aided Drug Design Methods for Developing Natural Compound-Based Therapeutics Against SARS-CoV-2

2.1 Introduction

2.2 What Is a Computer-Aided Drug Design Approach (CADD)? Types? Related Software?

2.3 How Has CADD Elevated the Entire Drug Development Pipeline?

2.4 Natural Compound Libraries Used for CADD Against SARS-CoV-2

2.5 Remarkable Successes of CADD in Designing Natural Compound-Based Therapeutics for COVID-19 Treatment

2.6 The Challenges and Scope Associated with CADD

2.7 Conclusions

Acknowledgments

References

Chapter 3 Therapeutic Targets of Host Factors for Potential COVID-19 Treatments

3.1 Introduction

3.2 General Replication Cycle of SARS-CoV-2

3.3 High-Content Screening of Host Factors

References

Chapter 4 Phytocompounds: A Paradigm Shift as Therapeutics for COVID-19

4.1 Introduction

4.2 Alkaloids

4.3 Phenolics

4.4 Terpenes

4.5 Organosulfur Compounds

4.6 Conclusions

Acknowledgments

References

Chapter 5 Flavonoids as Potential Therapeutic Agents Against the SARS-CoV-2 Infection: An Overview

5.1 Introduction

5.2 Flavonoids and Their Classification

5.3 SARS-CoV-2, Related Pathologies and Lead Drug Targets

5.4 Flavonoids as Therapeutics Against SARS-CoV-2

5.5 Conclusions

References

Chapter 6 Antiviral Activities of Flavonoids Against COVID-19 and Other Virus-Causing Ailments

6.1 Introduction

6.2 Types of Flavonoids

6.3 Respiratory Virus

6.4 Effects on Different Organs

6.5 Effects of Flavonoids

6.6 Conclusions

References

Chapter 7 Potential Therapeutic Effects of Flavonoids Against the COVID-19 Infection: The Mode of Action

7.1 Introduction

7.2 Biological and Structural Organization of SARS-CoV-2

7.3 Druggability of SARS-CoV-2 and Treatment Opportunities

7.4 Discussion on the Potential Antiviral Properties of Flavonoids

7.5 Prospects of Using Flavonoids as Potential Anti-SARS-CoV Virus Agents

7.6 Conclusions

References

Chapter 8 Terpenes and Terpenoids: Potent Antiviral Agents Against SARS-CoV-2

8.1 Background

8.2 Initial Backdrop of the Disease

8.3 Initial Therapeutic Options in Coronavirus Treatment

8.4 Possible Disadvantages of Synthetic Medicines and Vaccines

8.5 Natural Products as a Therapeutic Option Against SARS-CoV-2

8.6 Terpene-A Natural Product

8.7 The Action of Terpenes Against SARS-CoV-2 (Selected Studies/Examples)

8.8 Terpenes from Marine Organisms: Potential Anti-SARS-CoV-2 Agents

8.9 Present Status of Use of Terpenes in Pharmaceutical Industries to Counter SARS-CoV-2 and Allied Viruses

8.10 Mechanism of Action of Terpenes and In Silico Approaches Against SARS-CoV-2

8.11 Prospects and Conclusive Remarks

References

Chapter 9 Phytonutrients and Secondary Metabolites to Cease SARS-CoV-2 Loop

9.1 Introduction

9.2 Phytochemicals

9.3 Phytonutrients and Secondary Metabolites

9.4 Sources and Functions of Phytonutrients and Secondary Metabolites with Antiviral Activity

9.5 Antiviral Activity of Phytonutrients and Secondary Metabolites Against SARS-CoV-2

9.6 Conclusions

References

Chapter 10 Treatment Strategies Against COVID-19 Using Bioactive Compounds and Plant Secondary Metabolites

10.1 Introduction

10.2 Genomic Organization of SARS-CoV-2

10.3 Life Cycle of SARS-CoV-2

10.4 Pathogenesis of SARS-CoV-2

10.5 Treatment Strategies of SARS-CoV-2

10.6 Ethnobotanically Important Plants Presenting Potent Antiviral Activity

10.7 Natural Composites Accustomed to Controlling SARS-CoV-2

10.8 Biotechnological Approaches to Enhance the Production of Secondary Metabolites

10.9 Conclusions and Future Recommendations

Compliance with Ethical Standards

References

Chapter 11 The Potential Contribution of Vitamin K as a Nutraceutical to Scale Down the Mortality Rate of COVID-19

11.1 Introduction

Vitamin K

11.3 The Deficiency of Vitamin K And COVID-19

11.4 Plausible Mechanisms for Vitamin K Against SARS-CoV-2

11.5 Vitamin K Antagonist

11.6 Biomarkers to Detect Vitamin K Deficiency

11.7 Vitamin K is a Potent Nutraceutical

11.8 Possible Potentials of Vitamin K as an Anti-COVID-19 Agent

11.9 Conclusions

References

Chapter 12 Gastrointestinal Symptoms in COVID-19 Patients: Prevention and Treatment

12.1 Introduction

12.2 Gastrointestinal Symptom Manifestations

12.3 Gastrointestinal Symptoms Management

12.4 Medicinal Plants are Commonly Used in Morocco to Treat Gastrointestinal Disorders

12.5 Major Issues Remain Largely Unexplored

12.6 Recommendations to Manage the Manifestation of Gastrointestinal Symptoms Induced by COVID-19

References

Chapter 13 Mechanisms and Management Options of Liver Injury in COVID-19: A Review

13.1 Introduction

13.2 Action Mechanisms

13.3 Management and Prevention

13.4 Conclusions

References

Chapter 14 Marine Species-Derived Bioactives Against Coronavirus Disease

14.1 Introduction

14.2 The Entry of SARS-CoV-2

14.3 Druggable Targets

14.4 Marine Bioactive Compounds

14.5 Conclusions

14.6 Limitations

References

Chapter 15 Potential Bioactive Compounds of Indian Flora Against SARS-CoV-2

15.1 Introduction

15.2 Phenolic Compounds

15.3 Terpenoids

15.4 Alkaloids

15.5 Conclusions

References

Chapter 16 Natural Product-Derived Active Compounds for the Management of COVID-19: A Summary from Indochina

16.1 Introduction

16.2 Natural Sources and Natural Products for COVID-19 Management

16.3 Current Research and Perspectives in Southeast Asia

16.4 Conclusions

References

Chapter 17 Novel Therapeutic Strategy Based on Nanomedicine Targeting Thrombosis for SARS-CoV-2

17.1 Introduction

17.2 Thrombus Formation in COVID-19 Patients

17.3 Antithrombotic Necessity and Strategy for COVID-19 Patients

17.4 Nanomedicine as a Novel Therapeutic Strategy for COVID-19

17.5 Vaccine-Induced Immune Thrombotic of COVID-19

17.6 Conclusions and Future Perspectives

Acknowledgments

References

Chapter 18 Nanomaterials in Combating Human Coronavirus Infections

18.1 Introduction

18.2 Coronavirus

18.3 Challenges Faced with Antiviral Therapy

18.4 Nanotechnology

18.5 Nanoparticles in the Viral Arena

18.6 Conventional Nanoparticles Strategically Adopted for Treating SARS-CoV-2

18.7 Other Possible Bio-Inspired Nanoparticles Strategically Adopted for the Treatment of SARS-CoV-2

18.8 Point-of-Care Devices

18.9 Affordability of Nanoparticle-Based Medicines

18.10 Conclusions

References

Chapter 19 Structural Insights into Drug Targets from MERS, SARS-CoV, and SARS-CoV-2 and Scope for Phytochemicals as Broad-Spectrum Antivirals and Immunomodulators

19.1 Introduction

19.2 Article Search and Methodology

19.3 Key Viral Proteins of Hcovs and Their Role in the Life Cycle of the Virus

19.4 Conservations of Key Viral Proteins among HCoVS

19.5 Conclusions

References

Chapter 20 Precision Phytochemicals for COVID-19-Induced Olfactory Dysfunction

20.1 Introduction

20.2 Symptoms of COVID-19

20.3 Chemosensory Dysfunction Caused by COVID-19

20.4 Phytochemicals with Anti-Inflammatory Effects

20.5 Phytochemicals with Binding Affinity with SARS-CoV-2

20.6 Signaling Pathways

20.7 Future Directions for Clinical Treatment Options with Precision Phytochemicals

References

Index